T0	Participants 52 56	PCI.
T1	Participants 204 245	percutaneous coronary intervention (PCI).
T2	Participants 323 472	5362 patients who had not been treated with clopidogrel to receive either cangrelor or placebo at the time of PCI, followed by 600 mg of clopidogrel.
T3	Participants 744 874	primary end point occurred in 185 of 2654 patients receiving cangrelor (7.0%) and in 210 of 2641 patients receiving placebo (8.0%)